Comparing the Efficacy and Safety of Medications in Adults with Hypertrophic Cardiomyopathy: a Systematic Review and Network Meta-analysis

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Aug 30

PMID 37645523

Authors

Keying Mi

Sijia Wu

Chanyuan Lv

Yongkang Meng

Wenchao Yin

Hongkai Li

Jiangbing Li

Haitao Yuan

Affiliations

Soon will be listed here.

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. The purpose of this study was to evaluate the efficacy and safety of several medications and recommend better drug treatments for adults with HCM.

Methods: A review of PubMed, Embase, the Cochrane Controlled Register of Trials (CENTRAL), ClinicalTrials.gov and CNKI databases was conducted for studies on the efficacy and safety of drugs for adults with HCM. A frequentist random effects model was used in this network analysis.

Results: This network meta-analysis included 7 studies assessing seven medications, 6 studies evaluating monotherapy and 1 study evaluating combination therapy. Based on the network meta-analysis results, xiaoxinbi formula plus metoprolol (MD -56.50% [-72.43%, -40.57%]), metoprolol (MD -47.00% [-59.07%, -34.93%]) and mavacamten (MD -34.50% [-44.75%, -24.25%]) significantly reduced the resting left ventricular outflow tract gradient (LVOTG) in comparison with placebo. Resting LVOTG could also be reduced with N-acetylcysteine (NAC). The incidence of adverse drug reactions was not significantly different between the placebo group and the treatment group.

Conclusion: For adults with HCM, the top 4 treatments included xiaoxinbi formula plus metoprolol, metoprolol, mavacamten and NAC.: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=374222], identifier [CRD42022374222].

Citing Articles

Successful Management of Intraoperative Cardiac Arrest in a Patient With Undiagnosed Hypertrophic Cardiomyopathy.

Mehdi N, Khallikane S, Bencharfa B, Bouchama A, Youssef Q Cureus. 2024; 16(11):e73930.

PMID: 39563691 PMC: 11576061. DOI: 10.7759/cureus.73930.

Long-term follow-up study on obstructive hypertrophic cardiomyopathy patients treated with disopyramide: evidences of a notable trend in symptom control within a real-world clinical setting.

Todde G, Dei L, Polizzi R, Gabrielli D, Canciello G, Romano S Front Cardiovasc Med. 2024; 11:1416600.

PMID: 39175632 PMC: 11340511. DOI: 10.3389/fcvm.2024.1416600.

References

Pilagov M, Heling L, Walklate J, Geeves M, Kad N . Single-molecule imaging reveals how mavacamten and PKA modulate ATP turnover in skeletal muscle myofibrils. J Gen Physiol. 2022; 155(1). PMC: 9674027. DOI: 10.1085/jgp.202213087. View

Lorenzini M, Anastasiou Z, OMahony C, Guttman O, Gimeno J, Monserrat L . Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiol. 2019; 5(1):73-80. PMC: 6902239. DOI: 10.1001/jamacardio.2019.4534. View

Maron B, Maron M . Hypertrophic cardiomyopathy. Lancet. 2012; 381(9862):242-55. DOI: 10.1016/S0140-6736(12)60397-3. View

Dybro A, Rasmussen T, Nielsen R, Andersen M, Jensen M, Poulsen S . Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021; 78(25):2505-2517. DOI: 10.1016/j.jacc.2021.07.065. View

Margara F, Psaras Y, Wang Z, Schmid M, Doste R, Garfinkel A . Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy. Sci Rep. 2022; 12(1):22501. PMC: 9797561. DOI: 10.1038/s41598-022-26889-2. View

Crilley J, Boehm E, Blair E, Rajagopalan B, Blamire A, Styles P . Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003; 41(10):1776-82. DOI: 10.1016/s0735-1097(02)03009-7. View

Packard E, de Feria A, Peshin S, Reza N, Owens A . Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy. Cardiol Ther. 2022; 11(4):491-507. PMC: 9652179. DOI: 10.1007/s40119-022-00283-5. View

Kawana M, Spudich J, Ruppel K . Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies. Front Physiol. 2022; 13:975076. PMC: 9548533. DOI: 10.3389/fphys.2022.975076. View

Palandri C, Santini L, Argiro A, Margara F, Doste R, Bueno-Orovio A . Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs. 2022; 82(8):889-912. PMC: 9209358. DOI: 10.1007/s40265-022-01728-w. View

10.

Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I . Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016; 18(9):1106-18. DOI: 10.1002/ejhf.541. View

11.

Ommen S, Mital S, Burke M, Day S, Deswal A, Elliott P . 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142(25):e533-e557. DOI: 10.1161/CIR.0000000000000938. View

12.

Zampieri M, Berteotti M, Ferrantini C, Tassetti L, Gabriele M, Tomberli B . Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Curr Heart Fail Rep. 2021; 18(4):169-179. DOI: 10.1007/s11897-021-00523-0. View

13.

Olivotto I, Oreziak A, Barriales-Villa R, Abraham T, Masri A, Garcia-Pavia P . Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 396(10253):759-769. DOI: 10.1016/S0140-6736(20)31792-X. View

14.

Steinfurt J, Nazer B, Aguilar M, Moss J, Higuchi S, Zarse M . Catheter ablation of short-coupled variant of torsade de pointes. Clin Res Cardiol. 2021; 111(5):502-510. PMC: 9054881. DOI: 10.1007/s00392-021-01840-z. View

15.

Sarkar S, Trivedi D, Morck M, Adhikari A, Pasha S, Ruppel K . The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin. Sci Adv. 2020; 6(14):eaax0069. PMC: 7124958. DOI: 10.1126/sciadv.aax0069. View

16.

Maron B, Rowin E, Maron M . Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annu Rev Med. 2022; 73:363-375. DOI: 10.1146/annurev-med-042220-021539. View

17.

Anderson R, Trivedi D, Sarkar S, Henze M, Ma W, Gong H . Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018; 115(35):E8143-E8152. PMC: 6126717. DOI: 10.1073/pnas.1809540115. View

18.

Gistri R, Cecchi F, Choudhury L, Montereggi A, Sorace O, Salvadori P . Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994; 74(4):363-8. DOI: 10.1016/0002-9149(94)90404-9. View

19.

Marian A, Braunwald E . Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017; 121(7):749-770. PMC: 5654557. DOI: 10.1161/CIRCRESAHA.117.311059. View

20.

Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F . Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2012; 127(5):575-84. DOI: 10.1161/CIRCULATIONAHA.112.134932. View